As I recall, Vioxx "legally" made those kind of claims because they did go through "randomized, double blind, placebo-controlled trials to prove effectiveness, data published in peer-reviewed journals". Their product was soon found to be a killer and the FDA you say is so essential let it remain on the market until over 60,000 deaths had been attributed to it - more than we lost in Vietnam and many times more than all the deaths attributed to supplements in the history of our country.
And the sorry SOB's at Merck decided to fight every single claim in court, arguing that if there was even a 10 percent chance that something else could have caused a death, then it could not be determined beyond a shadow of a doubt that Vioxx was to blame. So far, they have not paid out a single dime in damages. There is your darling FDA, FDA approved safe drug and a drug manufacturer who plays by "the rules" for you.
The mainstream line that you parrot sounds so reasonable until you realize just how the rules have been rigged to suppress dietary supplements and force our money and our lives into the lab created medicines and lifetimes of managed illness that is Big Pharma and mainstream western medicine.
Did you even bother to look at the Rain Forest Plant Database entry for Bitter Melon? Just in case you missed it, I will copy it for you below. What more proof, and how many more studies could anyone possibly want - except those that wish to use the rules to suppress natural competition of the things we encounter in nature.
"Double-blind, placebo controlled studies in peer reviewed journals" didn't do squat for a long line of FDA approved killers. That is just using the rules and the game, such as the many hundred million dollars it takes to get a "new drug' through trials, which all the FDA approved killers did because they have the money to do so and can get a patent and sole control on unnatural substances - and, given the track record, be assured that their FDA lapdogs will approve them and leave them on the market long enough to reap billions of dollars of profits regardless of the death toll.
Dietary supplements are not supposed to be treated as drugs! They are made up by and large from natural botanicals, vitamins and mineralsthings we have lived with for hundreds of thousands of years, not some lab created monstrosity that is unnatural to put in our bodies. That is why the DSHEA made them dietary supplements - so they could be treated as FOOD!
If the problem was merely claims, then why does the FDA allow other food items to make such claims and use the disclaimer, as provided by law, and yet not allow dietary supplements to do the same thing, as also provided by law the FDA chooses to selectively enforce? Except things like cherries - far too natural, I guess and not nearly as highly processed and genetically modified as the foods that have been allowed to use the exception.
The law is rigged. And yes there is a reason why the FDA exists. Let's hear that reason as given by the last FDA commissioner to stand up to pressure from the industry to approve unsafe drugs and to suppress natural alternatives:
"The FDA 'protects' the big drug companies and are subsequently rewarded, and using the government's police powers they attack those who threaten the big drug companies. People think that the FDA is protecting them.
What the FDA is doing and what the public thinks it is doing are as different as night and day."
Dr. Herbert Ley
Former U.S. FDA Commissioner
Corrupt FDA employees? No, by and large many of the lower level employees believe that what they are doing is right. Like most corrupt organizations, it is the ones at the top that are corrupt, having been bought off by gifts and promised of lucrative future jobs by those they are supposed to oversee.
Speaking of foods, when the drug makers are able to to make their lab created unnatural drugs as safe as our natural supplements, then come back and demand that they meet the same failed standards. Until then, don't try to feed us any more mainline crap, because we aren't swallowing it!
In case you missed it, here is what the FDA is seizing and protecting us from while they leave Fosamax, Avandia, Gardasil and Aspartame on the market:
Bitter Melon (Momordica charantia
Family: Cucurbitaceae Genus:Momordica Species:charantia Synonyms:Momordica chinensis, M. elegans, M. indica, M. operculata, M. sinensis, Sicyos fauriei Common Names: bitter melon, papailla, melao de sao caetano, bittergourd, balsam apple, balsam pear, karela, k'u kua kurela, kor-kuey, ku gua, pava-aki, salsamino, sorci, sorossi, sorossie, sorossies, pare, peria laut, peria Part Used: whole plant, fruit, seed
HERBAL PROPERTIES AND ACTIONS
fights free radicals
Decoction: 1 cup 1-2 times daily 1 cup 1-2 times daily
kills cancer cells
Tincture: 1-3 ml twice daily 1-3 ml twice daily
kills leukemia cells
Capsules: 1 g twice daily
reduces blood sugar
reduces blood pressure
lowers body temperature
promotes milk flow
Bitter melon grows in tropical areas, including parts of the Amazon, east Africa, Asia, and the Caribbean, and is cultivated throughout South America as a food and medicine. It's a slender, climbing annual vine with long-stalked leaves and yellow, solitary male and female flowers borne in the leaf axils. The fruit looks like a warty gourd, usually oblong and resembling a small cucumber. The young fruit is emerald green, turning to orange-yellow when ripe. At maturity, the fruit splits into three irregular valves that curl backwards and release numerous reddish-brown or white seeds encased in scarlet arils. The Latin name Momordica means "to bite," referring to the jagged edges of the leaves, which appear as if they have been bitten. All parts of the plant, including the fruit, taste very bitter.
TRIBAL AND HERBAL MEDICINE USES
In the Amazon, local people and indigenous tribes grow bitter melon in their gardens for food and medicine. They add the fruit and/or leaves to beans and soup for a bitter or sour flavor; parboiling it first with a dash of salt may remove some of the bitter taste. Medicinally, the plant has a long history of use by the indigenous peoples of the Amazon. A leaf tea is used for diabetes, to expel intestinal gas, to promote menstruation, and as an antiviral for measles, hepatitis, and feverish conditions. It is used topically for sores, wounds, and infections and internally and externally for worms and parasites.
In Brazilian herbal medicine, bitter melon is used for tumors, wounds, rheumatism, malaria, vaginal discharge, inflammation, menstrual problems, diabetes, colic, fevers, worms. It is also used to induce abortions and as an aphrodisiac. It is prepared into a topical remedy for the skin to treat vaginitis, hemorrhoids, scabies, itchy rashes, eczema, leprosy and other skin problems. In Mexico, the entire plant is used for diabetes and dysentery; the root is a reputed aphrodisiac. In Peruvian herbal medicine, the leaf or aerial parts of the plant are used to treat measles, malaria, and all types of inflammation. In Nicaragua, the leaf is commonly used for stomach pain, diabetes, fevers, colds, coughs, headaches, malaria, skin complaints, menstrual disorders, aches and pains, hypertension, infections, and as an aid in childbirth.
Bitter melon contains an array of biologically active plant chemicals including triterpenes, proteins, and steroids. One chemical has clinically demonstrated the ability to inhibit the enzyme guanylate cyclase that is thought to be linked to the cause of psoriasis and also necessary for the growth of leukemia and cancer cells. In addition, a protein found in bitter melon, momordin, has clinically demonstrated anticancerous activity against Hodgkin's lymphoma in animals. Other proteins in the plant, alpha- and beta-momorcharin and cucurbitacin B, have been tested for possible anticancerous effects. A chemical analog of these bitter melon proteins has been developed, patented, and named "MAP-30"; its developers reported that it was able to inhibit prostate tumor growth. Two of these proteins-alpha- and beta-momorcharin-have also been reported to inhibit HIV virus in test tube studies. In one study, HIV-infected cells treated with alpha- and beta-momorcharin showed a nearly complete loss of viral antigen while healthy cells were largely unaffected. The inventor of MAP-30 filed another patent which stated it was "useful for treating tumors and HIV infections . . . " Another clinical study showed that MAP-30's antiviral activity was also relative to the herpes virus in vitro.
In numerous studies, at least three different groups of constituents found in all parts of bitter melon have clinically demonstrated hypoglycemic (blood sugar lowering) properties or other actions of potential benefit against diabetes mellitus. These chemicals that lower blood sugar include a mixture of steroidal saponins known as charantins, insulin-like peptides, and alkaloids. The hypoglycemic effect is more pronounced in the fruit of bitter melon where these chemicals are found in greater abundance.
To date, close to 100 in vivo studies have demonstrated the blood sugar-lowering effect of this bitter fruit. The fruit has also shown the ability to enhance cells' uptake of glucose, to promote insulin release, and to potentiate the effect of insulin. In other in vivo studies, bitter melon fruit and/or seed has been shown to reduce total cholesterol. In one study, elevated cholesterol and triglyceride levels in diabetic rats were returned to normal after 10 weeks of treatment.
Several in vivo studies have demonstrated the antitumorous activity of the entire plant of bitter melon. In one study, a water extract blocked the growth of rat prostate carcinoma; another study reported that a hot water extract of the entire plant inhibited the development of mammary tumors in mice. Numerous in vitro studies have also demonstrated the anticancerous and antileukemic activity of bitter melon against numerous cell lines, including liver cancer, human leukemia, melanoma, and solid sarcomas.
Bitter melon, like several of its isolated plant chemicals, also has been documented with in vitro antiviral activity against numerous viruses, including Epstein-Barr, herpes, and HIV viruses. In an in vivo study, a leaf extract increased resistance to viral infections and had an immunostimulant effect in humans and animals, increasing interferon production and natural killer cell activity.
In addition to these properties, leaf extracts of bitter melon have demonstrated broad-spectrum antimicrobial activity. Various extracts of the leaves have demonstrated in vitro antibacterial activities against E. coli, Staphylococcus, Pseudomonas, Salmonella, Streptobacillus, and Streptococcus; an extract of the entire plant was shown to have antiprotozoal activity against Entamoeba histolytica. The fruit and fruit juice have demonstrated the same type of antibacterial properties and, in another study, a fruit extract demonstrated activity against the stomach ulcer-causing bacteria Helicobacter pylori.
Many in vivo clinical studies have demonstrated the relatively low toxicity of all parts of the bitter melon plant when ingested orally. However, toxicity and even death in laboratory animals has been reported when extracts are injected intravenously. Other studies have shown extracts of the fruit and leaf (ingested orally) to be safe during pregnancy. The seeds, however, have demonstrated the ability to induce abortions in rats and mice, and the root has been documented as a uterine stimulant in animals. The fruit and leaf of bitter melon have demonstrated an in vivo antifertility effect in female animals; and in male animals, to affect the production of sperm negatively.
CURRENT PRACTICAL USES
Over the years scientists have verified many of the traditional uses of this bitter plant that continues to be an important natural remedy in herbal medicine systems. Bitter melon capsules and tinctures are becoming more widely available in the United States and are employed by natural health practitioners for diabetes, viruses, colds and flu, cancer and tumors, high cholesterol, and psoriasis. Concentrated fruit and seed extracts can be found in capsules and tablets, as well as whole herb/vine powders and extracts in capsules and tinctures.
BITTER MELON (leaf/stem) PLANT SUMMARY
Main Preparation Method: leaf decoction or capsules
Main Actions (in order):
anticancerous, antiviral, antibacterial, digestive stimulant, hypoglycemic
for viral infections (HIV, herpes, Epstein Barr, hepatitis, influenza, and measles)
for bacterial infections (Staphylococcus, Streptococcus, and Salmonella)
as a bitter digestive aid (for dyspepsia and sluggish digestion)
Other Properties/Actions Documented by Traditional Use:
antifungal, antiparasitic, antivenin, bitter, cardiotonic (tones, balances, strengthens the heart), digestive stimulant, emetic (causes vomiting), menstrual stimulator, purgative (strong laxative), vermifuge (expels worms)
Cautions: It lowers blood sugar levels and has abortive and contraceptive effects.
Traditional Preparation: 1 cup of a standard leaf or whole herb decoction is taken one or two times daily, or 1-3 ml of a 4:1 tincture is taken twice daily. Powdered leaf in tablets or capsules - 1 to 2 g can be substituted, if desired. The traditional South American remedy for diabetes is to juice 1-2 fresh bitter melon fruits and drink twice daily. For seed or fruit extracts in capsules or tinctures, follow the label instructions.
Bitter melon traditionally has been used as an abortive and has been documented with weak uterine stimulant activity; therefore, it is contraindicated during pregnancy.
This plant has been documented to reduce fertility in both males and females and should therefore not be used by those undergoing fertility treatment or seeking pregnancy.
The active chemicals in bitter melon can be transferred through breast milk; therefore, it is contraindicated in women who are breast feeding.
All parts of bitter melon (especially the fruit and seed) have demonstrated in numerous in vivo studies that they lower blood sugar levels. As such, it is contraindicated in persons with hypoglycemia. Diabetics should check with their physicians before using this plant and use with caution while monitoring their blood sugar levels regularly as the dosage of insulin medications may need adjusting.
Although all parts of the plant have demonstrated active antibacterial activity, none have shown activity against fungi or yeast. Long-term use of this plant may result in the die-off of friendly bacteria with resulting opportunistic overgrowth of yeast (Candida). Cycling off the use of the plant (every 21-30 days for one week) may be warranted, and adding probiotics to the diet may be beneficial if this plant is used for longer than 30 days.
Drug Interactions: Bitter melon may potentiate insulin and anti-diabetic drugs and cholesterol-lowering drugs.
for diabetes, dysentery, fever, hypertension, malaria, rheumatism, worms
Quoted References on Bitter Melon
10.Momordica charantia L. Cucurbitaceae. "Papailla", "Balsam pear". Fruit edible cooked. Plant decoction used for colic, and worms; infusion of fruit and flowers used for hepatitis. Seed pulp mixed with lard as a suppurative (SOU). Considered vermicide, stomachic, emmenagogue, and very effective in the expulsion of Trichocephalos. Fruit decoction used as febrifuge and emetic (PEA). Leaf decoction used by the "Cuna" for measles (RVM), by Brazilians for fever, itch, and sores (BDS). Seeds and pericarp contain saponin glycosides which produce elaterin and alkaloids, which causes vomiting and diarrhea (LAE). Leaf infusion a common folk remedy for diabetes around Iquitos (AYA). TRAMIL cites it as relatively POISONOUS (TRA). On the patent for Compound Q for AIDS, as a source of momocharin. Also contains rosmarinic acid, with antiviral activity and calceolarioside and verbascoside."
Third-Party Research on Bitter Melon
Available third-party documentation and research on bitter melon can be found at PubMed. A partial listing of the published research on bitter melon is shown below:
Antimicrobial Actions (virus, bacteria, fungi):
Vashishta, A., et al. "In vitro refolded napin-like protein of Momordica charantia expressed in Escherichia coli displays properties of native napin." Biochim. Biophys. Acta. 2006; 1764(5): 847-55.
Das, P., et al. "Screening of antihelminthic effects of Indian plant extracts: a preliminary report." J. Altern. Complement. Med. 2006 Apr; 12(3): 299-301.
Schmourlo, G., et al. “Screening of antifungal agents using ethanol precipitation and bioautography of medicinal and food plants.” J. Ethnopharmacol. 2005 Jan; 96(3): 563
Jiratchariyakul, W., et al. "HIV inhibitor from Thai bitter gourd." Planta Med. 2001 Jun; 67(4): 350-3.
Zheng, Y. T., et al. “Alpha-momorcharin inhibits HIV-1 replication in acutely but not chronically infected T-lymphocytes.” Zhongguo Yao Li Xue Bao. 1999; 20(3): 239-43.
Frame, A. D., et al. “Plants from Puerto Rico with anti-Mycobacterium tuberculosis properties.” P. R. Health Sci. J. 1998; 17(3): 243–52.
Khan, M. R., et al. “Momordica charantia and Allium sativum: Broad spectrum antibacterial activity.” Korean J. Pharmacog. 1998; 29(3): 155–58.
Bourinbaiar, A. S., et al. “The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against Herpes simplex virus in vitro.” Biochem. Biophys. Res. Commun. 1996; 219(3): 923–29.
Omoregbe, R. E., et al. “Antimicrobial activity of some medicinal plants’ extracts on Escherichia coli, Salmonella paratyphi and Shigella dysenteriae.” Afr. J. Med. Med. Sci. 1996; 25(4): 373–75.
Lee-Huang, S., et al. “Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31.” Proc. Natl. Acad. Sci. 1995; 92(19): 8818–22.
Dong, T. X., et al. “Ribosome inactivating protein-like activity in seeds of diverse Cucurbitaceae plants.” Indian J. Exp. Biol. 1993; 25(3): 415–19.
Zhang, Q. C. “Preliminary report on the use of Momordica charantia extract by HIV patients.” J. Naturopath. Med. 1992; 3: 65–9.
Hussain, H. S. N., et al. “Plants in Kano ethomedicine: Screening for antimicrobial activity and alkaloids.” Int. J. Pharmacog. 1991; 29(1): 51–6.
Huang, T. M., et al. “Studies on antiviral activity of the extract of Momordica charantia and its active principle.” Virologica. 1990; 5(4): 367–73.
Lee-Huang, S. “MAP 30: A new inhibitor of HIV-1 infection and replication.” FEBS Lett. 1990; 272(1–2): 12–18.
Takemoto, D. J. “Purification and characterization of a cytostatic factor with anti-viral activity from the bitter melon.” Prep. Biochem. 1983; 13(4): 371–93.
Takemoto, D. J., et al. “Purification and characterization of a cytostatic factor from the bitter melon Momordica charantia.” Prep. Biochem. 1982; 12(4): 355-75.
Anticancerous & Cytotoxic Actions:
Hwang, Y., et al. "Momordin I, an inhibitor of AP-1, suppressed osteoclastogenesis through inhibition of NF-kappaB and AP-1 and also reduced osteoclast activity and survival." Biochem. Biophys. Res. Commun. 2005 Nov; 337(3): 815-23.
Yasui, Y., et al. “Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells.” Prostaglandins Leukot. Essent. Fatty Acids. 2005 Aug; 73(2): 113-9.
Ike, K., et al. “Induction of interferon-gamma (IFN-gamma) and T helper 1 (Th1) immune response by bitter gourd extract.” J. Vet. Med. Sci. 2005; 67(5): 521-4.
Nagasawa, H., et al. “Effects of bitter melon (Momordica charantia) or ginger rhizome (Zingiber offifinale Rosc.) on spontaneous mammary tumorigenesis in SHN mice.” Am. J. Clin. Med. 2002; 30(2–3): 195–205.
Kim, J. H., et al. “Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells.” Anticancer Res. 2002 May-Jun; 22(3): 1885-9.
Tazzari, P. L., et al. “An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.” Haematologica. 1999; 84(11): 988-95.
Lee, D. K., et al. “Momordins inhibit both AP-1 function and cell proliferation.” Anticancer Res. 1998 Jan-Feb; 18(1A): 119-24.
Terenzi, A., et al. “Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumor activity against CD30+ tumor cells in vitro and in SCID mice.” Br. J. Haematol. 1996; 92(4): 872–79.
Bolognesi, A., et al. “Induction of apoptosis by ribosome-inactivating proteins and related immunotoxins.” Int. J. Cancer. 1996 Nov; 68(3): 349-55.
Battelli, M. G., et al. “Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line.” Int. J. Cancer. 1996 Feb; 65(4): 485-90.
Lee-Huang, S., et al. “Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon.” Gene. 1995; 161(2):151–56.
Cunnick, J. E., et al. “Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia).” Cell Immunol. 1990 Apr; 126(2): 278-89.
Zhu, Z. J., et al. “Studies on the active constituents of Momordica charantia l.” Yao. Hsueh. Hsueh. Pao. 1990; 25(12): 898–903.
Stirpe, F., et al. “Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.” Br. J. Cancer. 1988 Nov; 58(5): 558-61.
Takemoto, D. J., et al. “Purification and characterization of a cytostatic factor with anti-viral activity from the bitter melon. Part 2.” Prep Biochem. 1983; 13(5): 397-421.
Takemoto, D. J., et al. “The cytotoxic and cytostatic effects of the bitter melon (Momordica charantia) on human lymphocytes.” Toxicon. 1982; 20: 593–99.
Takemoto, D. J., et al. “Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts.” Enzyme. 1982; 27(3): 179–88.
Takemoto, D. J., et al. “Partial purification and characterization of a guanylate cyclase inhibitor with cytotoxic properties from the bitter melon (Momordica charantia).” Biochem. Biophys. Res. Commun. 1980; 94(1): 332–39.
Claflin, A. J., et al. “Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).” Proc. Natl. Acad. Sci. 1978; 75(2): 989–93.
Vesely, D. L., et al. “Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abbreviata).” Biochem. Biophys. Res. Commun. 1977; 77(4): 1294–99.
Antidiabetic & Hypoglycemic Actions:
Omar, S., et al. "Hypoglycemic effect of the seeds of Momordica charantia." Fitoterapia. 2007; 78(1): 46-7.
Ojewole, J., et al. "Hypoglycaemic and hypotensive effects of Momordica charantia Linn (Cucurbitaceae) whole-plant aqueous extract in rats." Cardiovasc. J. S. Afr. 2006 Sep-Oct; 17(5): 227-32.
Mahomoodally, M., et al. "Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of d-glucose, l-tyrosine and fluid transport across rat everted intestinal sacs in vitro." J. Ethnopharmacol. 2006 Sep 26;
Lans, C. "Ethnomedicines used in Trinidad and Tobago for urinary problems and diabetes mellitus." J. Ethnobiol. Ethnomedicine. 2006 Oct 13; 2:45.
Chuang, C., et al. "Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPARalpha in bitter gourd (Momordica charantia L.)." J. Biomed. Sci. 2006 Nov; 13(6): 763-72.
Krawinkel, M., et al. "Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia." Nutr. Rev. 2006; 64(7 Pt 1): 331-7.
Harinantenaina, L., et al. "Momordica charantia constituents and antidiabetic screening of the isolated major compounds." Chem. Pharm. Bull. 2006; 54(7): 1017-21.
Abd El Sattar, E., et al. "Some toxicological studies of Momordica charantia L. on albino rats in normal and alloxan diabetic rats." J. Ethnopharmacol. 2006 Nov; 108(2): 236-42.
Yibchok-Anun. S., et al. "Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities." Biol. Pharm. Bull. 2006 Jun;29(6):1126-31.
Jung, M., et al. "Antidiabetic agents from medicinal plants." Curr. Med. Chem. 2006; 13(10): 1203-18.
Kumar, G., et al. "Effect of bitter gourd and spent turmeric on constituents of glycosaminoglycans in different tissues in streptozotocin induced diabetic rats." Mol. Cell. Biochem. 2006 Jun; 286(1-2) :53-8.
Reyes, B., et al. "Anti-diabetic potentials of Momordica charantia and Andrographis paniculata and their effects on estrous cyclicity of alloxan-induced diabetic rats." J. Ethnopharmacol. 2006 Apr; 105(1-2): 196-200.
Khan, B., et al. "Hypogylcemic activity of aqueous extract of some indigenous plants." Pak. J. Pharm. Sci. 2005; 18(1): 62-4.
Zheng, Z.X., et al. “The hypoglycemic effects of crude polysaccharides extract from Momordica charantia in mice.” Wei Sheng Yan Jiu. 2005 May; 34(3): 361-3.
Reyes, B. A., et al. “Anti-diabetic potentials of Momordica charantia and Andrographis paniculata and their effects on estrous cyclicity of alloxan-induced diabetic rats.” J. Ethnopharmacol. 2005 Nov 16;
Sathishsekar, D., et al. “Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats.” Biol. Pharm. Bull. 2005; 28(6): 978-83.
Shetty, A. K., et al. “Effect of bitter gourd (Momordica charantia) on glycaemic status in streptozotocin induced diabetic rats.” Plant Foods Hum. Nutr. 2005 Sep; 60(3): 109-12.
Kumar Shetty, A., et al. “Bitter gourd (Momordica charantia) modulates activities of intestinal and renal disaccharidases in streptozotocin-induced diabetic rats.” Mol. Nutr. Food Res. 2005; 49(8): 791-6.
Chaturvedi, P., et al. “Effect of Momordica charantia on lipid profile and oral glucose tolerance in diabetic rats.” Phytother. Res. 2004; 18(11): 954-6.
Vikrant, V., et al. “Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats.” J. Ethnopharmacol. 2001; 76(2): 139–43.
Miura, T., et al. “Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice.” J. Nutr. Sci. Vitaminol. 2001; 47(5): 340–44.
Raza, H., et al. “Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract.” J. Biochem. Mol. Toxicol. 2000; 14(3): 131–39.
Ahmad, N., et al. “Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients.” Bangladesh Med. Res. Counc. Bull. 1999; 25(1): 11–13.
Ahmed, I., et al. “Effects of Momordica charantia fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat.” Diabetes Res. Clin. Pract. 1998; 40(3): 145–51.
Sarkar, S., et al. “Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes.” Pharmacol. Res. 1996; 33(1): 1–4.
Ali, L., et al. “Studies on hypoglycemic effects of fruit pulp, seed and whole plant of Momordica charantia on normal and diabetic model rats.” Planta Med. 1993; 59(5): 408–12.
Akhtar, M. S. “Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes.” J. Pak. Med. Assoc. 1982; 32(4): 106–7.
Cholesterol-Lowering & Antioxidant Actions:
Nerurkar, P., et al. "Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2." Br. J. Pharmacol. 2006 Aug; 148(8): 1156-64.
Chan, L. L., et al. “Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression.” J. Nutr. 2005; 135(11): 2517-23.
Chen, Q., et al. “Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines.” Br. J. Nutr. 2005; 93(5): 747-54.
Hsieh, C. L., et al. “Inhibitory effect of some selected nutraceutic herbs on LDL glycation induced by glucose and glyoxal.” J. Ethnopharmacol. 2005 Dec; 102(3): 357-63.
Chaturvedi, P. “Role of Momordica charantia in maintaining the normal levels of lipids and glucose in diabetic rats fed a high-fat and low-carbohydrate diet.” Br. J. Biomed. Sci. 2005; 62(3): 124-6.
Sathishsekar, D., et al. “Antioxidant properties of Momordica charantia (bitter gourd) seeds on streptozotocin induced diabetic rats.” Asia Pac. J. Clin. Nutr. 2005; 14(2): 153-8.
Ansari, N. M., et al. “Antioxidant activity of five vegetables traditionally consumed by South-Asian migrants in Bradford, Yorkshire, UK.” Phytother. Res. 2005; 19(10): 907-11.
Senanayake, G.V. et al. “The effects of bitter melon (Momordica charantia) extracts on serum and liver lipid parameters in hamsters fed cholesterol-free and cholesterol-enriched diets.” J. Nutr. Sci. Vitaminol. 2004 Aug; 50(4): 253-7.
Ahmed, I., et al. “Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (Karela) fruit extract in streptozotocin-induced diabetic rats.” Diabetes Res. Clin. Pract. 2001; 51(3):155–61.
Jayasooriya, A. P., et al. “Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets.” J. Ethnopharmacol. 2000; 72 (1–2): 331.
Dengiz, G. O., et al. “Effects of Momordica charantia L. (Cucurbitaceae) on indomethacin-induced ulcer model in rats.” Turk. J. Gastroenterol. 2005 Jun; 16(2): 85-88.
Yesilada, E., et al. “Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity.” J. Ethnopharmacol. 1999; 66(3): 289–93.
Girini, M. M., et al. “Effect of graded doses of Momordica charantia seed extract on rat sperm: scanning electron microscope study.” J. Basic Clin. Physiol. Pharmacol. 2005; 16(1): 53-66.
Bhakuni, D. S., et al. “Screening of Indian plants for biological activity: Part XIII.” Indian J. Exp. Biol. 1988; 26(11): 883RY–904
Koentjoro-Soehadi, T., et al. “Perspectives of male contraception with regards to Indonesian traditional drugs.” Proc. Second National Congress of Indonesian Society of Andrology. 1982; Aug. 2–6: 12.
Dixit, V. P., et al. “Effects of Momordica charantia fruit extract on the testicular function of dog.” Planta Med. 1978; 34: 280–86.
Prakash, A. O., et al. “Screening of Indian plants for antifertility activity.” Indian J. Exp. Biol. 1976; 14: 623–626.
Stepka, W., et al. “Antifertility investigation on Momordica.” Lloydia. 1974; 37(4): 645c
Jamwal, K. S., et al. “Preliminary screening of some reputed abortifacient indigenous plants.” Indian J. Pharmacy 1962; 24: 218–20.
Copied under the freedom of non-commercial use doctrine.